Cepheid
SUNNYVALE, California and GENEVA, February 3, 2011 - Cepheid (Nasdaq: CPHD) and FIND (Foundation for Innovative New
Diagnostics) today announced a new collaboration to accelerate the
development of a rapid molecular test for the measurement of human
immunodeficiency virus (HIV) viral load.
SUNNYVALE, California, April 7, 2010 - Cepheid (Nasdaq: CPHD) will initiate European launch of its newest
addition to the GeneXpert(R) family of molecular diagnostic testing systems,
the GeneXpert Infinity-48, at the 20th annual European Congress of Clinical
Microbiology & Infectious Diseases (ECCMID) in Vienna, Austria.
SUNNYVALE, California, January 4 - Cepheid (Nasdaq: CPHD) today announced it has been granted Emergency Use
Authorization (EUA) from the U.S.
SUNNYVALE, California - Oncology Test Further Highlights Broad Market Applicability of GeneXpert System
Cepheid (Nasdaq: CPHD) today announced the release of its improved Xpert(R) BCR-ABL Monitor test to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices.
SUNNYVALE, California - Test for Mycobacterium tuberculosis (TB) Expected to Highlight Broad On-Demand CE IVD Test Menu at Booth #611
Cepheid (Nasdaq: CPHD) today announced speaker and program highlights for its symposium, "Patient Management in the Era of Rapid Diagnostics," which the company will host at the 19th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place in Finland next month.
